Adriamycin
Hepatocellular Carcinoma
Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
VA Office of Research and Development
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05842174CT.gov Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07302919CT.gov Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07314372CT.gov FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07157969CT.gov ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC | — | Recruiting | — | — | — |
NCT06485466CT.gov TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06503250CT.gov A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization | — | Completed | — | — | — |
NCT06397235CT.gov DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC | — | Recruiting | — | — | — |
NCT05776875CT.gov Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | — | Terminated | — | — | — |
NCT05824975CT.gov A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | — | Recruiting | — | — | — |
NCT05766605CT.gov Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial | — | Unknown | — | — | — |
Show 50 more trialsShow fewer
NCT05435014CT.gov T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma | — | Suspended | — | — | — |
NCT05233358CT.gov HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure | — | Unknown | — | — | — |
NCT05093920CT.gov Role of DEB-TACE Versus c-TACE in Treatment of HCC | — | Unknown | — | — | — |
NCT03937830CT.gov Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma | — | Active Not Recruiting | — | — | — |
NCT04522544CT.gov Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC | — | Recruiting | — | — | — |
NCT04472767CT.gov Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04244552CT.gov A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | — | Terminated | — | — | — |
NCT04803019CT.gov Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04174781CT.gov Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC | — | Unknown | — | — | — |
NCT04103398CT.gov TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT04143191CT.gov Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC | — | Unknown | — | — | — |
NCT04048317CT.gov Effectiveness of Drug Eluting TACE in Primary HCC | — | Unknown | — | — | — |
NCT04008797CT.gov A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | — | Active Not Recruiting | — | — | — |
NCT03563170CT.gov QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | — | Withdrawn | — | — | — |
NCT03533582CT.gov Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | — | Active Not Recruiting | — | — | — |
NCT03145558CT.gov TATE Versus TACE in Intermediate Stage HCC | — | Terminated | — | — | — |
NCT03338647CT.gov SBRT or TACE for Advanced HCC | — | Unknown | — | — | — |
NCT03017326CT.gov Paediatric Hepatic International Tumour Trial | — | Active Not Recruiting | — | — | — |
NCT02856126CT.gov HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC | — | Completed | — | — | — |
NCT02524119CT.gov LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT02460991CT.gov A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT02527772CT.gov Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT02638857CT.gov Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03007225CT.gov Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients | — | Completed | — | — | — |
NCT01721941CT.gov TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT02006030CT.gov Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02112656CT.gov Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT02018757CT.gov Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC | — | Unknown | — | — | — |
NCT01861912CT.gov Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT01840592CT.gov Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | — | Active Not Recruiting | — | — | — |
NCT01489410CT.gov Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT01655693CT.gov Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01381211CT.gov Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
NCT01966133CT.gov TACE as an Adjuvant Therapy After Hepatectomy for HCC | — | Unknown | — | — | — |
NCT01015833CT.gov Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer | — | Completed | — | — | — |
NCT01116635CT.gov Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT01004978CT.gov Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT01016054CT.gov A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer | — | Terminated | — | — | — |
NCT01042041CT.gov Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer | — | Completed | — | — | — |
NCT00770536CT.gov AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR | — | Completed | — | — | — |
NCT01125020CT.gov Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation | — | Unknown | — | — | — |
NCT00877071CT.gov LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed | — | Completed | — | — | — |
NCT00988195CT.gov Study of Pegylated Human Recombinant Arginase for Liver Cancer | — | Completed | — | — | — |
NCT00617981CT.gov Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT00471965CT.gov Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients | — | Completed | — | — | — |
NCT00441376CT.gov A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver | — | Completed | — | — | — |
NCT00390195CT.gov Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC) | — | Unknown | — | — | — |
NCT00108953CT.gov A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00057382CT.gov T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients | — | Terminated | — | — | — |
NCT00183742CT.gov Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | VA Office of Research and Development | Approved | BB · 70 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
| Penpulimab | West China Hospital | P3 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Adriamycin in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/adriamycin-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →